| 11 | ESFS 233% v2,8M c.005 H .09 | znewcar1 | 11/05/2019 4:36:34 PM |
| 10 | ESFS Financials 07/16/2014 07:24:57 Eco-Safe | Emylers | 07/16/2014 8:24:53 AM |
| 9 | Latest Eco-Safe Systems USA (ESFS) Headlines | Stock_Tracker | 03/09/2014 6:46:21 PM |
| 8 | ESFS 0.017 Stock Charts $ESFS 1 Month Chart | chartguy89 | 03/07/2014 3:04:32 AM |
| 7 | ESFS Stock Charts Last: UNCH Wednesday, February | chartguy89 | 02/26/2014 12:17:58 AM |
| 6 | .045x.05 check this link out and read for your | Danederlander | 08/20/2013 1:53:14 PM |
| 5 | They going to land Eco-safe system in China check | Danederlander | 08/18/2013 1:24:06 PM |
| 4 | ESFS HOD .079! Shares are tight. Looking for | windmillpower | 08/05/2013 4:37:31 PM |
| 3 | Why ESFS is a screaming buy. ESFS recently pushed | windmillpower | 08/04/2013 3:18:43 PM |
| 2 | This is company http://www.ecosafeusa.com and | windmillpower | 08/04/2013 12:40:45 PM |
| 1 | ESFS .043. Great time to buy. Edward Nixon is new | windmillpower | 08/04/2013 12:26:52 PM |
Recent Articles
- InnoCare Pharma Unveils Promising BCL2 Inhibitor Data at ASH
- Rio2 Limited Upsizes Bought Deal Financing to C$166 Million
- Rio2 Expands Financing Deal to C$166 Million Amid Demand
- Understanding the Recent Class Action Against Gauzy Ltd. (GAUZ)
- Gauzy Ltd. Faces Class Action as Financial Trouble Looms
- Lead Your Claim: aTyr Pharma Investors Have Options
- MetaComp Secures $22 Million to Fortify Cross-Border Payments
- Enhanced Quality of Life and Survival Outcomes for Ivonescimab
- Cathie Wood's Ark Invest Shifts Focus to Baidu from Tesla
- Nidec Corporation Investors: Key Updates and Actions to Take
- Investors Presented with a Class Action Opportunity Against ARE
- Hong Kong Unites After Fire, Showcases Resilience and Hope
- Examining the Worth of Alexander & Baldwin's Shareholder Deal
- Innovative Wellness Gifts from SKG for a Healthier Holiday Season
- TDECU Welcomes New Strategic Leaders to Board for Growth
- EnWave Corporation's Upcoming Q4 2025 Financial Report Plans
- Cygnus Metals Limited Issues Performance Rights to Employees
- Netcapital Inc. Implements New Incentive Program for Growth
- Insights on Alvotech's Class Action Investigation by Rosen Law
- Monument Mining's AGM: Key Highlights and Future Directions
- RetinalGenix Technologies Welcomes M. Cory Zwerling as New CFO
- ALT5 Sigma Corp Faces Investigation Over Securities Concerns
- Legal Alert: DeFi Technologies Class Action Lawsuit Update
- Market Updates: Key Stocks Drawing Investor Interest Today
- Hormel Foods Corporation Investors: Taking Action on Legal Rights
- Investigation on Nidec Corporation: Investors Aware of Claims
- Brookfield Corporation Unveils C$1 Billion Medium-Term Notes
- Marquis Software Faces Data Breach Concerns Affecting Customers
- California Consumers Face $59 Billion Gas Overcharge Crisis
- Cali-Power Football Team Triumphs in Court Over Title Rights
- Ascentage Pharma Showcases Long-Term Efficacy Data for Olverembatinib
- Promising Results from Phase III POLARIS-1 Study of Olverembatinib
- Promising New Data on Olverembatinib for CML Treatment
- Promising Update on Olverembatinib for CML-CP Patients
- Olverembatinib's Significant Long-Term Impact for CML Patients
- CoreWeave, Inc.: Investigating Claims and Market Impact
- Hong Kong Rallies Together to Rebuild After Tragic Fire
- RetinalGenix Welcomes M. Cory Zwerling as New CFO and Interim COO
- Star Group, L.P. Sees Growth in 2025 Financial Results
- Star Group, L.P. Achieves Revenue Growth in Fiscal 2025
- Shaquille O'Neal's Innovative Journey from Basketball to Tech
- BioArctic's Leqembi Listed as Innovative Drug in China
- Innovent Biologics Delivers Breakthrough in Psoriasis Treatment
- Vermilion Energy Expands Financial Strategy Through Share Sales
- Morgan Dudley Joins Stargaze as Creative Advisor for New Era
- Understanding the Securities Class Action for Telix Pharmaceuticals
- Trump's Involvement in Paramount's Bid for Warner Bros. Discovery
- Investing in Deutsche Bank: Strong Returns Over Five Years
- Transform Your Investment: The Journey of $1000 in OEF Growth
- BioArctic's Leqembi Approved for China's Innovative Drug List
